TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Tvardi Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.97−0.04 (-3.96%)

Close on Oct 19, 2026

Market cap: $9.10M
P/E (TTM): –
Dividend yield: 0.00%

Tvardi Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Cash & Equivalents	21	32	23	64	14	32	19	16	10	14	16	53	12	1.12	4.10
Short-Term Investments	10	–	–	–	154	149	137	146	83	46	92	–	–	–	–
Cash & Short-Term Investments	31	38	101	157	237	251	218	183	93	58	107	53	12	1.12	4.10
Receivables	–	0.41	2.77	3.26	–	–	–	–	0	–	–	–	–	–	–
Inventory	–	0.90	2.82	2.38	2.58	–	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	0.73	0.07	8.15	16	2.52	12	8.86	4.81	1.64	1.53	1.73	0.29	2.14	–	–
Total Current Assets	32	32	116	169	173	195	166	168	95	61	109	53	15	–	–
Property, Plant & Equipment	0.05	0.08	3.32	0.43	0.63	0.84	0.70	0.88	1.18	1.61	1.26	2.08	2.83	–	–
Gross Property, Plant & Equipment	–	–	4.99	1.84	1.79	2.38	2.03	2.01	1.94	9.70	8.28	8.28	8.24	–	–
Accumulated Depreciation	–	–	-1.67	-1.41	-1.16	-1.54	-1.33	-1.13	-0.76	-8.09	-7.02	-6.19	-5.42	–	–
Long-Term Investments	–	–	–	–	70	71	63	21	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.14	0.22	4.86	1.55	2.97	4.28	3.04	–	–	–	–	–	–	–	–
Intangible Assets	0.32	0.39	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.02	0.02	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Assets	32	35	126	182	247	271	233	191	97	64	111	56	18	–	–
Accounts Payable	3.22	2.19	12	9.60	5.63	4.89	9.10	4.37	3.83	4.74	1.97	0.52	0.68	–	–
Accrued Expenses	7.71	8.08	–	–	–	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.12	0.10	–	1.92	1.76	1.60	0.97	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	–	–	–	–	–	22	27	–	–	–	1.45	3.48	–	–
Total Current Liabilities	11	10	26	23	18	18	43	40	8.51	12	5.27	3.40	5.43	–	–
Long-Term Leases	0.09	0.20	6.09	–	1.92	3.67	3.35	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.20	0	6.09	1.92	3.67	5.28	4.32	–	–	–	–	–	–	–	–
Total Liabilities	11	41	69	23	20	22	46	57	10	13	5.85	4.27	–	–	–
Preferred Stock	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–
Common Stock	0.01	0.00	0.01	0.05	0.05	0.05	0.05	0.04	0.03	0.03	0.03	0.02	0.00	–	–
Additional Paid-In Capital	131	1.10	742	727	709	641	587	428	307	213	210	132	8.38	–	–
Retained Earnings	-110	-92	-685	-566	-481	-392	-401	-294	-220	-162	-105	-80	-62	–	–
Comprehensive Income & Other	0.01	–	-0.26	-1.67	-0.36	0.07	0.17	-0.11	-0.07	0.00	-0.04	0	–	–	–
Shareholders' Equity	21	-91	-62	159	228	249	187	134	87	51	105	52	-54	-58	-52
Total Equity	21	-91	-62	159	228	249	187	134	87	51	105	52	-54	-58	-52
Total Liabilities & Equity	32	35	126	182	247	271	233	191	97	64	111	56	–	–	–
Shares Outstanding(shares)	9.38	2.57	4.54	4.48	4.46	4.16	3.89	3.30	2.72	2.27	2.27	1.90	0.36	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 51.9%

Financial strength

Current ratio: 1.87
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 173.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.09
Dividend yield: 0.00%